ATC Group: A07EB01 Cromoglicic acid

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A07EB01 in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A07 Antidiarrheals, intestinal antiinflammatory/antiinfective agents
3 A07E Intestinal antiinflammatory agents
4 A07EB Antiallergic agents, excl. corticosteroids
5 A07EB01 Cromoglicic acid

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.8 g

Active ingredients in A07EB01

Active Ingredient Description
Cromoglicic acid

Sodium cromoglicate (Cromoglicic acid) inhibits the activation of many of the cell types involved in the development and progression of asthma. Thus, sodium cromoglicate inhibits the release of inflammatory mediators including cytokines from mast cells and reduces the chemotactic activity of eosinophils and neutrophils.

Related product monographs

Title Information Source Document Type  
NALCROM Capsule Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

Canada (CA)

Estonia (EE)

Malta (MT)

Netherlands (NL)

New Zealand (NZ)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.